Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 3/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804052 | 1.00 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL3776750 | 1.00 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL4852056 | 0.96 | EPOR (0.46) | EPORFOLH1ITGB3ITGA2BTPSAB1 | |
| SCHEMBL10477497 | 0.96 | EPOR (0.46) | EPORFOLH1ITGB3ITGA2BTPSAB1 | |
| SCHEMBL9574165 | 0.96 | EPOR (0.46) | EPORFOLH1ITGB3ITGA2BTPSAB1 | |
| SCHEMBL3222447 | 0.95 | EPOR (0.52) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL10608191 | 0.92 | EPOR (0.51) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL375887 | 0.91 | TPSAB1 (0.53) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL4150947 | 0.91 | TPSAB1 (0.53) | EPORFOLH1LTA4HITGB3ITGA2B | |
| SCHEMBL3820596 | 0.91 | TPSAB1 (0.53) | EPORFOLH1LTA4HITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-2916837-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-16 | — | — | EP | claimed |
| WO-2014074421-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-15 | — | — | WO | claimed |
| US-12629423-B2 | Olfactory delivery scaffolds using antisense oligonucleotides and methods for making and using same | OLFERA CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250269038-A1 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | OLFERA CORPORATION | 2025-08-28 | — | — | US | disclosed |
| US-20250249106-A1 | Olfactory Delivery Scaffolds Using Peptides and Methods for Making and Using Same | OLFERA CORPORATION | 2025-08-07 | — | — | US | disclosed |
| WO-2025096244-A1 | OLFACTORY DELIVERY SCAFFOLDS AND METHODS FOR MAKING AND USING SAME | OLFERA CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| US-12059468-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-12006358-B2 | Antibody against advanced glycation end products and use thereof | BLOOM TECHNOLOGY CORPORATION (JP) | 2024-06-11 | — | — | US | disclosed |
| EP-4321177-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| WO-1986004334-A1 | IMMUNOREGULATORY PEPTIDES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-07-31 | — | — | WO | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
| EP-0169300-A1 | Process for preparation of alpha-alkyl amino acids | MERCK & CO. INC. (US) | 1986-01-29 | — | — | EP | disclosed |
| US-4508921-A | Process for preparation of alpha-alkyl amino acids | MERCK & CO., INC. (US) | 1985-04-02 | — | — | US | disclosed |
| EP-0117797-A1 | Nitroso ureas, process for their preparation and their therapeutic use | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1984-09-05 | — | — | EP | disclosed |
| WO-1984003088-A1 | NEW NITROSOUREAS, PREPARATION METHOD THEREOF AND THEIR APPLICATION IN THERAPY | CENTRE NAT RECH SCIENT (FR) | 1984-08-16 | — | — | WO | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
| US-4119620-A | Novel dipeptide derivatives, salts thereof, and method of measuring enzyme activity | AJINOMOTO CO., INC. (JP) | 1978-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269038-A1 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | OR51E2, OR10J3, GAP43 | EPOR 921/4885FOLH1 2912/4885LTA4H 2336/4885 |
| US-12629423-B2 | Olfactory delivery scaffolds using antisense oligonucleotides and methods for making and using same | OR10J3, OR51E2, TAS2R43 | EPOR 246/4885FOLH1 4180/4885LTA4H 3027/4885 |
| US-20250249106-A1 | Olfactory Delivery Scaffolds Using Peptides and Methods for Making and Using Same | OR51E2, OR10J3, GAP43 | EPOR 593/4885FOLH1 2357/4885LTA4H 1643/4885 |
| US-12059468-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | EPOR 1137/4885FOLH1 53/4885LTA4H 4531/4885 |
| US-12006358-B2 | Antibody against advanced glycation end products and use thereof | AGER, GLA, GID4 | EPOR 400/4885FOLH1 154/4885LTA4H 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.